Fluconazole Exposure in Critically Ill Patients and the Value of Therapeutic Drug Monitoring
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Plasma concentrations of fluconazole in critically ill patients
研究概览
简要总结
Fluconazole is the first-line agent in the treatment of invasive candidiasis. Studies showed inappropriate drug exposure causes high mortality in critically ill patients. Under-dosing and ineffective fluconazole trough serum concentrations were found in a recent retrospective study. Variability in fluconazole exposure can be easily measured with therapeutic drug monitoring. For patient groups who are at risk for drug underexposure, therapeutic drug monitoring can be valuable regards decreasing mortality.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is 18 years or older.
- •Treatment with fluconazole.
- •Written informed consent obtained from patient.
- •Written informed consent obtained from representative of patient.
排除标准
- •Blood sampling not possible
结局指标
主要结局
Plasma concentrations of fluconazole in critically ill patients
时间窗: Up to one month
Plasma concentrations of fluconazole will be determined using a validated method involving LC-MS/MS
次要结局
未报告次要终点
研究者
Jan-Willem C Alffenaar
Associate Professor of Medicine
University Medical Center Groningen
